US · EW · MEDICAL - DEVICES
Edwards Lifesciences Corporation (EW) intrinsic value and stock valuation
$101.85as of 2026-11-21 · Mkt cap 51.23B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Edwards Lifesciences Corporation DCF and intrinsic value
InvestorsCraft values EW with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from EW’s statements →
Edwards Lifesciences Corporation Graham Number
Graham Number: $27.02d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Cardinal Health, Inc. (CAH) $272.81
- argenx SE (ARGX) $925.70
- Becton, Dickinson and Company (BDX) $212.78
- Haleon plc (HLN) $9.07
- Agilent Technologies, Inc. (A) $170.38
- Veeva Systems Inc. (VEEV) $266.22
- Alcon Inc. (ALC) $74.31
- DexCom, Inc. (DXCM) $79.32
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $5.38B | $5.23B |
| Operating income | $1.64B | $1.38B | $1.43B | $1.7B | $1.61B |
| Net income | $1.07B | $4.17B | $1.4B | $1.52B | $1.5B |
| EPSd | $1.83M | $6.97M | $2.3M | $2.44M | $2.38M |
| Operating cash flow | $1.6B | $542.3M | $895.8M | $1.22B | $1.73B |
| Capital expenditure | -$-260.2M | -$-252.4M | -$-266.3M | -$-264.8M | -$-329.8M |
| Free cash flow | $1.34B | $289.9M | $629.5M | $953.4M | $1.4B |
| Total assets | $13.7B | $13.1B | $9.36B | $8.29B | $8.5B |
| Total debt | $705.4M | $700M | $685.1M | $691.3M | $690.3M |
| Net debt | -$-2.23B | -$-2.35B | -$-447.2M | -$-77.7M | -$-172.5M |
| Total equity | $10.3B | $10.1B | $6.72B | $5.81B | $5.84B |
| Cash and short-term investments | $4.23B | $3.98B | $1.63B | $1.22B | $1.47B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $5.38B | $5.23B |
| Cost of revenue | $1.33B | $1.12B | $1.04B | $1.17B | $1.23B |
| Gross profit | $4.74B | $4.32B | $3.97B | $4.22B | $4.01B |
| Research and development expenses | $1.08B | $1.05B | $962.9M | $945.2M | $903.1M |
| Selling, general and administrative expenses | $2.09B | $1.79B | $1.58B | $1.57B | $1.49B |
| Other expenses | -$-59.9M | $101.1M | $0.00 | $0.00 | $0.00 |
| Operating expenses | $3.1B | $2.94B | $2.55B | $2.51B | $2.4B |
| Cost and expenses | $4.43B | $4.06B | $3.58B | $3.68B | $3.62B |
| Interest income | $148.4M | $120.3M | $67.2M | $35.5M | $17.4M |
| Interest expense | $0.00 | $19.8M | $17.6M | $26.2M | $24.8M |
| Depreciation and amortization | $156.6M | $155.2M | $144.9M | $166.8M | $163.3M |
| Ebitda | $1.43B | $1.72B | $1.53B | $1.96B | $1.89B |
| Operating income | $1.64B | $1.38B | $1.43B | $1.7B | $1.61B |
| Total other income/expenses, net | -$-363.3M | $169.4M | -$-54.9M | $65M | $91.6M |
| Income before tax | $1.27B | $1.55B | $1.37B | $1.77B | $1.7B |
| Income tax expense | $216.9M | $152.1M | $152.4M | $245.5M | $198.9M |
| Net income | $1.07B | $4.17B | $1.4B | $1.52B | $1.5B |
| Weighted average shares outstanding | $584.8M | $597.7M | $606.7M | $619M | $623.3M |
| Weighted average diluted shares outstanding | $585.8M | $599.3M | $609.4M | $624.2M | $631.2M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $4.23B | $3.98B | $1.63B | $1.22B | $1.47B |
| Net receivables | $912.1M | $727.4M | $828.1M | $699.1M | $664.9M |
| Inventory | $1.13B | $1.09B | $903.5M | $875.5M | $726.7M |
| Total current assets | $6.74B | $6.29B | $4.04B | $3.1B | $3.18B |
| Property, plant and equipment, net | $1.91B | $1.78B | $1.68B | $1.73B | $1.64B |
| Goodwill and intangible assets | $2.9B | $2.95B | $1.54B | $1.45B | $1.49B |
| Long-term investments | $773.9M | $307.9M | $583.9M | $1.24B | $1.83B |
| Total non-current assets | $6.96B | $6.77B | $5.33B | $5.2B | $5.32B |
| Total assets | $13.7B | $13.1B | $9.36B | $8.29B | $8.5B |
| Accounts payable | $227.5M | $197.4M | $186.6M | $201.9M | $204.5M |
| Short-term debt | $24.5M | $23.4M | $22.9M | $25.5M | $25.5M |
| Deferred revenue | $27.2M | $53.7M | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $1.81B | $1.51B | $1.2B | $1.02B | $1.03B |
| Long-term debt | $680.9M | $676.6M | $662.2M | $665.8M | $664.8M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $1.55B | $1.49B | $1.45B | $1.46B | $1.63B |
| Capital lease obligations | $82.6M | $102.3M | $88.1M | $95M | $94.6M |
| Total liabilities | $3.36B | $2.99B | $2.64B | $2.49B | $2.67B |
| Common stock | $658.7M | $654.8M | $650.5M | $646.3M | $642M |
| Retained earnings | $14.2B | $13.2B | $8.99B | $7.59B | $6.07B |
| Accumulated other comprehensive income (loss) | -$-238.3M | -$-244.5M | -$-242.8M | -$-254.9M | -$-157.7M |
| Total equity | $10.3B | $10.1B | $6.72B | $5.81B | $5.84B |
| Total investments | $2.06B | $1.24B | $1.08B | $1.69B | $2.44B |
| Total debt | $705.4M | $700M | $685.1M | $691.3M | $690.3M |
| Net debt | -$-2.23B | -$-2.35B | -$-447.2M | -$-77.7M | -$-172.5M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $1.07B | $4.17B | $1.4B | $1.52B | $1.5B |
| Depreciation and amortization | $156.6M | $155.2M | $144.9M | $139.6M | $134.8M |
| Stock-based compensation | $158.1M | $162.3M | $139.4M | $126.8M | $109.3M |
| Change in working capital | $154.6M | -$-259.3M | -$-526.3M | -$-421.4M | $145.3M |
| Accounts receivable | -$-23M | $121.2M | -$-141.2M | -$-84.1M | -$-112.4M |
| Inventory | $50.7M | -$-256.1M | -$-289M | -$-213.4M | $19M |
| Accounts payable | $395.1M | $89.5M | $146M | -$-21.4M | $195.2M |
| Net cash provided by operating activities | $1.6B | $542.3M | $895.8M | $1.22B | $1.73B |
| Investments in property, plant and equipment | -$-260.2M | -$-282.4M | -$-266.3M | -$-264.8M | -$-329.8M |
| Acquisitions, net | $0.00 | -$-1.06B | -$-95.2M | $0.00 | $329.8M |
| Net cash used for investing activities | -$-712.9M | $2.31B | $173.8M | $252.3M | -$-1.72B |
| Common stock issued | $174.1M | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-893.4M | -$-1.16B | -$-879.6M | -$-1.73B | -$-512.8M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-956.8M | -$-983M | -$-711M | -$-1.58B | -$-356.3M |
| Net change in cash | -$-119.3M | $1.91B | $375.4M | -$-94.8M | -$-332.8M |
| Cash at end of period | $2.94B | $3.06B | $1.15B | $772.6M | $867.4M |
| Operating cash flow | $1.6B | $542.3M | $895.8M | $1.22B | $1.73B |
| Capital expenditure | -$-260.2M | -$-252.4M | -$-266.3M | -$-264.8M | -$-329.8M |
| Free cash flow | $1.34B | $289.9M | $629.5M | $953.4M | $1.4B |
Line items
Line items
Line items
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- CEO
- Bernard J. Zovighian
- Employees
- 16K
- Beta
- 0.85
Included in
Explore
Frequently asked questions
What is the intrinsic value of Edwards Lifesciences Corporation (EW)?
Edwards Lifesciences Corporation (EW) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is EW undervalued?
EW trades at a price of $101.85 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.